Author(s):
Meenu Vijayan, Deb Narayan Dutta, Haridas Nair, Narmadha MP, Sheejamol VS
Email(s):
dduttadeb07@gmail.com
DOI:
10.52711/0974-360X.2025.00707 
Address:
Meenu Vijayan1, Deb Narayan Dutta2*, Haridas Nair2, Narmadha MP1, Sheejamol VS3
1Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.
2Department of Radiation Oncology, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.
3Department of Biostatistics, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 10,
Year - 2025
ABSTRACT:
Background: Radiotherapy-induced nausea and vomiting (RINV) significantly affects overall health outcomes in cancer patients. Olanzapine has substantial potential in controlling RINV by blocking multiple receptors that regulate vomiting. This pilot study aims to determine the appropriate sample size for the future main trial and assess the feasibility and safety of olanzapine in combination with ondansetron for initiating phase III randomized trial. Methods: Prospective, randomized, placebo-controlled study to be conducted at tertiary care teaching hospital in South India. Based on a statistical thumb rule, we enrolled 24 patients, test group (n=12) and control group (n=12). Simple randomization was employed for allocating the patients to receive either a placebo plus ondansetron or olanzapine 5mg plus ondansetron. All the adverse drug reactions were observed and graded for intensity by the scale of CTCAE v5. An appropriate formula to determine the sample size was used based on the percentage of occurrence of nausea between two groups. Results: Nausea was less common in olanzapine arm (16.7%) than control group (41.7%) (p=0.371). and was found to be clinically significant. Both groups exhibit similar levels of toxicity. Patients in the control group reported grade 2 nausea (33.3%) where in patients in olanzapine arm reported grade 1 (16.7%) nausea. Additionally, 100% of the patients who were recruited complied with the treatment plan. Conclusion: This pilot study confirms that olanzapine combined with ondansetron shows promise for managing RINV with a favourable safety profile. A full study enrolling with minimum sample size of 152 patients would be required to fully characterize the role of olanzapine in improving patient care during radiotherapy.
Cite this article:
Meenu Vijayan, Deb Narayan Dutta, Haridas Nair, Narmadha MP, Sheejamol VS. Sample size calculation, Feasibility, and Safety profile with Olanzapine for preventing Radiation Induced Nausea and Vomiting: Pilot Study for phase III Randomized Placebo-controlled Trial – CTRI No/2022/01/039723. Research Journal of Pharmacy and Technology. 2025;18(10):4902-8. doi: 10.52711/0974-360X.2025.00707
Cite(Electronic):
Meenu Vijayan, Deb Narayan Dutta, Haridas Nair, Narmadha MP, Sheejamol VS. Sample size calculation, Feasibility, and Safety profile with Olanzapine for preventing Radiation Induced Nausea and Vomiting: Pilot Study for phase III Randomized Placebo-controlled Trial – CTRI No/2022/01/039723. Research Journal of Pharmacy and Technology. 2025;18(10):4902-8. doi: 10.52711/0974-360X.2025.00707 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-10-46
REFERENCES:
1. Clark-Snow RA. Danso MA. Dennis K. Dupuis LL. Dusetzina SB. Eng C.Feyer PC et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28): 3240-3261. doi: 10.1200/JCO.2017.74.4789.
2. Jacob R, Aswathy AB, Sivadas A. Prospective Randomized case control study of Oral Aprepitant for the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV). Research J. Pharm. and Tech. 2016; 9(12): 2180-2.doi:10.5958/0974-360X.2016.00441.8
3. Balaji EV, Selvan A. Cancer-A Historical Status, Government Regulation and Current Scenario of Socio-Economic Impact-Retrospective Study. Asian J. Pharm. Res.. 2018; 8(3): 133-5. doi: 10.5958/2231-5691.2018.00023.0
4. Yadav AR, Mohite SK. Cancer-A silent killer: An overview. Asian J. Pharm. Res. 2020; 10(3): 213-6. doi: 10.5958/2231-5691.2020.00036.2
5. Dhakad GG, Patil GD, Nikum AC, Shirsat SP. Review on Radiation Therapy on Cancer. Res. J. Pharm. Pharmacodyn. 2022; 14(1): 4-12. doi: 10.52711/2321-5836.2022.00002
6. Roila F. Molassiotis A. Herrstedt J.Aapro M. Gralla R.Bruera E et al. MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(5): 119-33. doi: 10.1093/annonc/mdw270.
7. Jordan K. Roila F.Warr D. Celio L. Navari RM. Hesketh PJ et al. Update MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017; 25(1): 277-288. doi: 10.1007/s00520-016-3313-0.
8. Swapna B, Kumar SV. Personalized medicine-a novel approach in cancer therapy Research J. Pharm. and Tech. 2017;10(1):341-5. doi: 10.5958/0974-360X.2017.00069.5
9. Pathak P,Mahal R,Kohli a,Nimbaran V. A Quasi Experimental Study to Evaluate the Effectiveness of Progressive Muscle Relaxation on Anxiety and Depression among Hospitalised Cancer Patients receiving Radiotherapy. Asian J. Nurs. Educ. Res. 2013; 3(1): 42-46
10. Iranmanesh S, Shamsi A. The Relationship between Type of Cancer and Parent's Psychosocial Risks. Asian J. Nurs. Educ. 2014; 4(4): 495-501
11. Kaur J. An exploratory study to assess the quality of life among cancer patients of district bathinda, Punjab. Asian J. Nurs. Educ. 2015; 5(1): 18-22. doi: 10.5958/2349-2996.2015.00005.1
12. Vijayalakshmi K. Assessment of depression among cancer patients. Asian J. Nurs. Educ. 2018; 8(1): 11-4. doi: 10.5958/2349-2996.2018.00004.6
13. Navari RM. Qin R. Ruddy KJ.Liu H. Powell SF. Bajaj M et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 375(2): 134-42. doi: 10.1056/NEJMoa1515725.
14. Mizukami N. Yamauchi M. Koike K. Watanabe A. Ichihara K. Masumori N et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014; 47(3): 542-50. doi: 10.1016/j.jpainsymman.2013.05.003
15. Schmitt LG. Amarnath SR. Late Effects of Pelvic Radiation Therapy in the Female Patient: A Comprehensive Review. Appl Rad Oncol. 2023; 3 :13-24. doi:10.1016/10.37549/aro-d-23-00016
16. Menon UK. Gopalakrishnan S. N Unni CS. Ramachandran R. Poornima B.Sasidharan A.Ashika MS et al. Pilot of a questionnaire study regarding perception of undergraduate medical students towards online classes: Process and perspectives. J Family Med Prim Care. 2021; 10(5): 2016-2021. doi: 10.4103/jfmpc.jfmpc_2141_20.
17. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005; 4(4): 287-91. doi: 10.1002/pst.185
18. Lancaster GA. Dodd S. Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2): 307-12. doi: 10.1111/j..2002.384.doc.x.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Accessed from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
20. Zhang X-L. Ying J-E. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug. Current Oncology. 2022; 29(11): 8235-8243. doi: 10.3390/curroncol29110650
21. Yanai T. Iwasa S. Hashimoto H. Ohyanagi F.Takiguchi T. Takeda K et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol. 2018; 23(2): 382-388. doi: 10.1007/s10147-017-1200-4.
22. Hashimoto H. Abe M.Tokuyama O. Mizutani H. Uchitomi Y.Yamaguchi Tet al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2020; 21(2): 242-9. doi: 10.1016/S1470-2045(20)30014-0.
23. Gao J.Zhao J.Jiang C.Chen F. Zhao L et al. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Supportive Care in Cancer. 2022; 30(7): 6225-32. doi: 10.1007/s00520-022-07067-6
24. Common terminology criteria for adverse events. U.S. department of health and human services. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
25. Vijayalakshmi DT, Asha K, Mounika BU, Babu KN. An Evaluation of quality of life in patients on concurrent Chemo radiotherapy with Cisplatin in Head and Neck Cancer-A Prospective Observational Study. Asian J. Pharm. Res. 2018; 8(1): 21-31. doi: 10.5958/2231-5691.2018.00005.9
26. Yoodee J. Permsuwan U.Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Critical reviews in oncology/hematology. 2017; 112: 113-25. doi: 10.1016/j.critrevonc.2017.02.017
27. Hesketh PJ.Kris MG.Basch E.Bohlke K. Barbour SY. Clark-Snow RA et al. Antiemetics: ASCO guideline update. Journal of Clinical Oncology. 2020; 38(24): 2782-97. doi: 10.1200/JCO.20.03378